HomeApproved Therapies

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera

NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera
|
Less than 1 min read
|
Updated:

Santhera Obtains Favorable NICE Final Guidance for AGAMREE (Vamorolone) as a Therapeutic Option for Duchenne Muscular Dystrophy.

AGAMREE (vamorolone) has been recommended for use in the National Health Service (NHS) in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 and up by the National Institute for Health and Care Excellence (NICE), according to Santhera Pharmaceuticals.

Learn More: What is Agamree (vamorolone)? What is Agamree Used For?

- Follow Us -
DMDWarrioR Instagram
SourceSanthera
Author: Can Ekinci
Add DMDWarrior as a preferred Google source to see more of our trusted coverage.

Disclaimer: This article is for informational purposes only and does not provide medical advice. Patients and families should discuss treatment options and clinical trials with their healthcare professionals.

DMDWarrior Clinical Trials Hub now available in 10 languages, providing AI-assisted Duchenne clinical trial information worldwide.

Trending on DMDWarrioR- Duchenne News

Load more

Related Articles

Load more